Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/2002

01-08-2002 | Original Article

Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment

Authors: Hsin-Wei Chen, Hsing-I Huang, Yi-Ping Lee, Li-Li Chen, Hsiung-Kun Liu, Mei-Lien Cheng, Jy-Ping Tsai, Mi-Hua Tao, Chou-Chik Ting

Published in: Cancer Immunology, Immunotherapy | Issue 6/2002

Login to get access
Metadata
Title
Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment
Authors
Hsin-Wei Chen
Hsing-I Huang
Yi-Ping Lee
Li-Li Chen
Hsiung-Kun Liu
Mei-Lien Cheng
Jy-Ping Tsai
Mi-Hua Tao
Chou-Chik Ting
Publication date
01-08-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0283-5

Other articles of this Issue 6/2002

Cancer Immunology, Immunotherapy 6/2002 Go to the issue

Original Article

Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines

Original Article

Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell–leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination

Original Article

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses

Letter to the Editors

Immunogenicity of WT-1 peptides

Original Article

Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor

Review

Immature myeloid cells and cancer-associated immune suppression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits